Relationship between glycemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBITER 2

Allen J Taylor, Daming Zhu, Lance E Sullenberger, Hyun J Lee, Jeannie K Lee, Karen A Grace Cardiology Service, Walter Reed Army Medical Center, Washington, DC, USA Background: We previously reported in a placebo-controlled study that extended-release niacin slowed the progression of carotid atherosc...

Full description

Bibliographic Details
Main Authors: Allen J Taylor, Daming Zhu, Lance E Sullenberger, Hyun J Lee, Jeannie K Lee, Karen A Grace
Format: Article
Language:English
Published: Dove Medical Press 2007-03-01
Series:Vascular Health and Risk Management
Online Access:https://www.dovepress.com/relationship-between-glycemic-status-and-progression-of-carotid-intima-peer-reviewed-article-VHRM
_version_ 1819237020630777856
author Allen J Taylor
Daming Zhu
Lance E Sullenberger
Hyun J Lee
Jeannie K Lee
Karen A Grace
author_facet Allen J Taylor
Daming Zhu
Lance E Sullenberger
Hyun J Lee
Jeannie K Lee
Karen A Grace
author_sort Allen J Taylor
collection DOAJ
description Allen J Taylor, Daming Zhu, Lance E Sullenberger, Hyun J Lee, Jeannie K Lee, Karen A Grace Cardiology Service, Walter Reed Army Medical Center, Washington, DC, USA Background: We previously reported in a placebo-controlled study that extended-release niacin slowed the progression of carotid atherosclerosis when added to statin monotherapy. This analysis examines the relationship between glycemic status and the effects of niacin on common carotid intima-media thickness (CIMT) and HDL cholesterol.Methods: Post-hoc, subgroup analysis of ARBITER 2, a randomized, placebo-controlled trial of once-daily extended-release niacin (1000 mg) added to background statin therapy in 167 patients (mean age 67 years) with known coronary heart disease. The primary analysis was a comparison of the primary endpoint, the change in CIMT, between participants with either normal glycemic status, diabetes mellitus (DM) or the metabolic syndrome (MS).Results: Baseline cardiovascular risk variables were significantly worse in those with abnormal glycemic status, particularly among subjects with MS. Niacin increased HDL-C to a similar degree (~20%) across normals, DM and MS. Placebo-treated patients had the greatest CIMT progression, regardless of glycemic status. The lowest progression rate was observed in niacin treated patients with normal glycemic status. Among all niacin treated subjects, there was a significant linear relationship between change in CIMT and change in HDL-C (r = –0.16; p = 0.05), which was of similar magnitude in subgroups with normal glycemic status (r = –0.23; p = 0.08) and DM (r = –0.22; p = 0.17). In those with MS, there was no relationship between changes in HDL and CIMT, (r = 0.11; p = 0.44), whereas blood glucose was positive correlated to change in CIMT (r = 0.30; p = 0.04). In multivariable linear models controlling for MS characteristics and blood glucose changes, only the change in HDL independently predicted change in CIMT.Conclusions: During niacin treatment, increases in HDL-C are related to changes in CIMT in the setting of both normal glycemic status and diabetes mellitus.Keywords: atherosclerosis, risk factors, lipids, diabetes mellitus
first_indexed 2024-12-23T13:13:42Z
format Article
id doaj.art-2dd971bd6c704e1abe696c27d089a30e
institution Directory Open Access Journal
issn 1178-2048
language English
last_indexed 2024-12-23T13:13:42Z
publishDate 2007-03-01
publisher Dove Medical Press
record_format Article
series Vascular Health and Risk Management
spelling doaj.art-2dd971bd6c704e1abe696c27d089a30e2022-12-21T17:45:39ZengDove Medical PressVascular Health and Risk Management1178-20482007-03-01Volume 31591641471Relationship between glycemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBITER 2Allen J TaylorDaming ZhuLance E SullenbergerHyun J LeeJeannie K LeeKaren A GraceAllen J Taylor, Daming Zhu, Lance E Sullenberger, Hyun J Lee, Jeannie K Lee, Karen A Grace Cardiology Service, Walter Reed Army Medical Center, Washington, DC, USA Background: We previously reported in a placebo-controlled study that extended-release niacin slowed the progression of carotid atherosclerosis when added to statin monotherapy. This analysis examines the relationship between glycemic status and the effects of niacin on common carotid intima-media thickness (CIMT) and HDL cholesterol.Methods: Post-hoc, subgroup analysis of ARBITER 2, a randomized, placebo-controlled trial of once-daily extended-release niacin (1000 mg) added to background statin therapy in 167 patients (mean age 67 years) with known coronary heart disease. The primary analysis was a comparison of the primary endpoint, the change in CIMT, between participants with either normal glycemic status, diabetes mellitus (DM) or the metabolic syndrome (MS).Results: Baseline cardiovascular risk variables were significantly worse in those with abnormal glycemic status, particularly among subjects with MS. Niacin increased HDL-C to a similar degree (~20%) across normals, DM and MS. Placebo-treated patients had the greatest CIMT progression, regardless of glycemic status. The lowest progression rate was observed in niacin treated patients with normal glycemic status. Among all niacin treated subjects, there was a significant linear relationship between change in CIMT and change in HDL-C (r = –0.16; p = 0.05), which was of similar magnitude in subgroups with normal glycemic status (r = –0.23; p = 0.08) and DM (r = –0.22; p = 0.17). In those with MS, there was no relationship between changes in HDL and CIMT, (r = 0.11; p = 0.44), whereas blood glucose was positive correlated to change in CIMT (r = 0.30; p = 0.04). In multivariable linear models controlling for MS characteristics and blood glucose changes, only the change in HDL independently predicted change in CIMT.Conclusions: During niacin treatment, increases in HDL-C are related to changes in CIMT in the setting of both normal glycemic status and diabetes mellitus.Keywords: atherosclerosis, risk factors, lipids, diabetes mellitushttps://www.dovepress.com/relationship-between-glycemic-status-and-progression-of-carotid-intima-peer-reviewed-article-VHRM
spellingShingle Allen J Taylor
Daming Zhu
Lance E Sullenberger
Hyun J Lee
Jeannie K Lee
Karen A Grace
Relationship between glycemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBITER 2
Vascular Health and Risk Management
title Relationship between glycemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBITER 2
title_full Relationship between glycemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBITER 2
title_fullStr Relationship between glycemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBITER 2
title_full_unstemmed Relationship between glycemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBITER 2
title_short Relationship between glycemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBITER 2
title_sort relationship between glycemic status and progression of carotid intima media thickness during treatment with combined statin and extended release niacin in arbiter 2
url https://www.dovepress.com/relationship-between-glycemic-status-and-progression-of-carotid-intima-peer-reviewed-article-VHRM
work_keys_str_mv AT allenjtaylor relationshipbetweenglycemicstatusandprogressionofcarotidintimamediathicknessduringtreatmentwithcombinedstatinandextendedreleaseniacininarbiter2
AT damingzhu relationshipbetweenglycemicstatusandprogressionofcarotidintimamediathicknessduringtreatmentwithcombinedstatinandextendedreleaseniacininarbiter2
AT lanceesullenberger relationshipbetweenglycemicstatusandprogressionofcarotidintimamediathicknessduringtreatmentwithcombinedstatinandextendedreleaseniacininarbiter2
AT hyunjlee relationshipbetweenglycemicstatusandprogressionofcarotidintimamediathicknessduringtreatmentwithcombinedstatinandextendedreleaseniacininarbiter2
AT jeannieklee relationshipbetweenglycemicstatusandprogressionofcarotidintimamediathicknessduringtreatmentwithcombinedstatinandextendedreleaseniacininarbiter2
AT karenagrace relationshipbetweenglycemicstatusandprogressionofcarotidintimamediathicknessduringtreatmentwithcombinedstatinandextendedreleaseniacininarbiter2